Ernexa Therapeutics (ERNAW) Net Cash Flow (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Net Cash Flow data on file, last reported at $7.3 million in Q1 2026.

• Quarterly Net Cash Flow rose 3758.73% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (up 199.84% YoY) and the FY2025 annual result came in at $155000.0, up 101.56% from the prior year.
• Net Cash Flow climbed to $7.3 million in Q1 2026, from -$1.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $7.3 million in Q1 2026 to a low of -$6.2 million in Q3 2022.
• A 5-year average of -$458000.0 and a median of -$1.2 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow slumped 192.85% — and 2026, when it jumped 3758.73%.
• Tracing ERNAW's Net Cash Flow over 5 years: stood at $2.3 million in 2022, then jumped by 32.23% to $3.0 million in 2023, then tumbled by 183.83% to -$2.5 million in 2024, then jumped by 54.12% to -$1.2 million in 2025, then soared by 727.09% to $7.3 million in 2026.
• The last three Net Cash Flow figures came in at $7.3 million (Q1 2026), -$1.2 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.